The Company hereby submits Unaudited Financial Results for quarter ended 30 June, 2025 along with limited review report.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Simran Farms reported standalone revenue from operations of ₹20,494 lakhs for Q1 FY26, up about 16% from ₹17,641 lakhs in Q1 FY25. However, net profit plunged sharply to ₹71 lakhs (EPS ₹1.88) from ₹870 lakhs (EPS ₹22.95) a year ago, as finance costs jumped nearly 4x to ₹72 lakhs and raw material costs rose steeply. Operating profit before tax fell to ₹100 lakhs from ₹1,220 lakhs, indicating significant margin compression. The auditor (Khandelwal Kakani & Co.) issued an unmodified limited review report on both standalone and consolidated results, with no qualifications. Consolidated results include subsidiary Puregene Biotech Limited, which was not separately audited but deemed immaterial.
Despite healthy revenue growth, the sharp drop in profitability and rising finance costs are red flags that may weigh on the stock. Shareholders should note the resignation of the Whole Time Director (Mr. Kawaljeet Singh Bhatia) though he continues as a Non-Executive Director.